Reinhorn Daniel, Jacobi Oded, Icht Oded, Dudnik Elizabeth, Rotem Ofer, Zer Alona, Goldstein Daniel A
Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Immunotherapy. 2020 Mar;12(4):235-243. doi: 10.2217/imt-2019-0131. Epub 2020 Mar 19.
The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.
随着免疫检查点抑制剂（ICI）的引入，晚期非小细胞肺癌的治疗模式最近发生了变化。在某些情况下，继续治疗超过疾病进展期（TBP）是常见的做法。本研究的目的是评估与TBP相关的实际临床实践和结果。我们回顾性评估了接受ICI治疗的晚期非小细胞肺癌患者，并确定了接受超过疾病进展期治疗的患者。在纳入该分析的207例患者中，22%的患者接受了TBP。共有36%的患者获得了临床获益。共有27%的患者在接受TBP后无进展生存期超过6个月。一部分接受ICI超过疾病进展期治疗的患者获得了具有临床意义的反应，并实现了持久的疾病控制。
